BrightHeart

Company profile

About BrightHeart

BrightHeart is a global leader in artificial intelligence solutions for prenatal ultrasound, specializing in fetal cardiac screening. The company's B-Right AI Platform empowers clinicians and sonographers to deliver expert-level care during routine prenatal ultrasound examinations. The platform consists of two main products: B-Right Screen, which provides AI-powered analysis of key structural markers to identify signs of severe congenital heart defects with 96% detection accuracy, and B-Right Views, which offers automatic protocol completion tracking and AI detection of standard fetal heart views. The system integrates seamlessly into existing workflows as a plug-and-play solution compatible with major ultrasound manufacturers. BrightHeart's mission is to deliver expert-level ultrasound care worldwide, regardless of resources, settings, or expertise. The company addresses a critical healthcare challenge: congenital heart defects are the most common birth defects worldwide, with 2 children born with CHD every minute, yet up to 70% go undetected during pregnancy and nearly 50% of fetal cardiac scans are incomplete. Founded by pediatric cardiologists and healthcare technology experts, BrightHeart has achieved FDA clearance and CE marking for its products, with clinical validation published in peer-reviewed journals including Obstetrics & Gynecology. The company is backed by leading healthcare investors and has deployed its technology in major healthcare systems including Mount Sinai Health System.

Company description · BrightHeart official website

Mission. BrightHeart's mission is to empower perinatal healthcare professionals with innovative AI solutions that enhance the accuracy and efficiency of ultrasound assessments, ultimately improving patient outcomes. We aim to be the leading provider of AI-driven tools to transform perinatal care and ensure a brighter future for every child.